Mogroside IIIE, a novel anti-fibrotic compound, reduces pulmonary fibrosis through toll-like receptor 4 pathways

Journal of Pharmacology and Experimental Therapeutics

Volumn 361, Issue 2, 2017, Pages 268-279

  Tao, Lijun ^a   Yang, Jinyu ^a   Cao, Fengyan ^a   Xie, Haifeng ^c   Zhang, Mian ^a   Gong, Yanqing ^b   Zhang, Chaofeng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Chengdu Biopurity Phytochemicals Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; INTERLEUKIN 1BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MOGROSIDE IIIE; MYELOID DIFFERENTIATION FACTOR 88; PREDNISONE; SMOOTH MUSCLE ACTIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; 11-OXOMOGROSIDE III; ANTIINFLAMMATORY AGENT; GLYCOSIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; FIBROSING ALVEOLITIS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LUNG FIBROBLAST; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG MONITORING; FIBROBLAST; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG MONITORING; FIBROBLASTS; GLYCOSIDES; IDIOPATHIC PULMONARY FIBROSIS; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOLL-LIKE RECEPTOR 4;

EID: 85018172217     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.239137     Document Type: Article

References (48)

1. Alcorn JF, van der Velden J, Brown AL, McElhinney B, Irvin CG, and Janssen-Heininger YM (2009) c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 40:422-432.
2. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, et al. (2013) Toll-like receptor 4 signaling augments transforming growth factor-b responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 182:192-205.
3. Bocchino M, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, Gabrielli A, Sanduzzi A, and Avvedimento EV (2010) Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS One 5:e14003.
4. Bruce MC and Honaker CE (1998) Transcriptional regulation of tropoelastin expression in rat lung fibroblasts: changes with age and hyperoxia. Am J Physiol 274: L940-L950.
5. Chaudhary NI, Schnapp A, and Park JE (2006) Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173:769-776.
6. Chen M, Cheung FW, Chan MH, Hui PK, Ip SP, Ling YH, Che CT, and Liu WK (2012) Protective roles of Cordyceps on lung fibrosis in cellular and rat models. J Ethnopharmacol 143:448-454.
7. Chen XB, Zhuang JJ, Liu JH, Lei M, Ma L, Chen J, Shen X, and Hu LH (2011) Potential AMPK activators of cucurbitane triterpenoids from Siraitia grosvenorii Swingle. Bioorg Med Chem 19:5776-5781.
8. Committee of National Pharmacopoeia (2010) Pharmacopoeia of P.R. China, Chemical Industry Press, Beijing, China.
9. Derynck R and Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature 425:577-584.
10. Di R, Huang MT, and Ho CT (2011) Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model. J Agric Food Chem 59:7474-7481.
11. Fan H, Qi D, Yang M, Fang H, Liu K, and Zhao F (2013) In vitro and in vivo antiinflammatory effects of 4-methoxy-5-hydroxycanthin-6-one, a natural alkaloid from Picrasma quassioides. Phytomedicine 20:319-323.
12. Galuppo M, Esposito E, Mazzon E, Di Paola R, Paterniti I, Impellizzeri D, and Cuzzocrea S (2011) MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn Schmiedebergs Arch Pharmacol 384:21-37.
13. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, et al. (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117:3786-3799.
14. Gürbüzel M, Sayar I, Cankaya M, Gürbüzel A, Demirtas L, Bakirci EM, and Capoglu I (2016) The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats. Pharmacol Rep 68:378-382.
15. Hashimoto N, Jin H, Liu T, Chensue SW, and Phan SH (2004) Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 113:243-252.
16. Hay J, Shahzeidi S, and Laurent G (1991) Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65:81-94.
17. He Z, Gao Y, Deng Y, Li W, Chen Y, Xing S, Zhao X, Ding J, and Wang X (2012) Lipopolysaccharide induces lung fibroblast proliferation through Toll-like receptor 4 signaling and the phosphoinositide3-kinase-Akt pathway. PLoS One 7:e35926.
18. He Z, Zhu Y, and Jiang H (2009) Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res 10:126.
19. Huebener P and Schwabe RF (2013) Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta 1832:1005-1017.
20. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, et al. (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11:1173-1179.
21. Jin JS and Lee JH (2012) Phytochemical and pharmacological aspects of Siraitia grosvenorii, luo han kuo. Orient Pharm Exp Med 12:233-239.
22. Krebs J, Kolz A, Tsagogiorgas C, Pelosi P, Rocco PR, and Luecke T (2015) Effects of lipopolysaccharide-induced inflammation on initial lung fibrosis during open-lung mechanical ventilation in rats. Respir Physiol Neurobiol 212-214:25-32.
23. Li L, Li D, Xu L, Zhao P, Deng Z, Mo X, Li P, Qi L, Li J, and Gao J (2015) Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine 22:111-119.
24. Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S, and Hardie WD (2012) MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol 46:380-388.
25. Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, Fujiwara H, Tachibana I, Osaki T, and Hayashi S (2002) A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 283:L103-L112.
26. Moran N (2011) p38 Kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol 29:301.
27. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
28. Rhieu BH, Epperly MW, Cao S, Goff J, Shields D, Franicola D, Wang H, and Greenberger JS (2014) Improved longevity of hematopoiesis in long-term bone marrow cultures and reduced irradiation-induced pulmonary fibrosis in Toll-like receptor-4 deletion recombinant-negative mice. In Vivo 28:441-448.
29. Salaun B, Romero P, and Lebecque S (2007) Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 37:3311-3318.
30. Shi D, Zheng M, Wang Y, Liu C, and Chen S (2014) Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice. Pharm Biol 52:729-734.
31. Song KJ, Liao ZX, Liu YP, Chen XY, and Huang CH (2014) Effect of activation and apoptosis of mogroside on hepatic stellate cell. Zhongchengyao 36:481-484.
32. Sun BS, Chen YP, Wang YB, Tang SW, Pan FY, Li Z, and Sung CK (2012) Antiobesity effects of mogrosides extracted from the fruits of Siraitia grosvenorii (Cucurbitaceae). Afr J Pharm Pharmacol 6:1492-1501.
33. Sun X, Chen E, Dong R, Chen W, and Hu Y (2015) Nuclear factor (NF)-kB p65 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-b. Life Sci 122:8-14.
34. Suzuki YA, Murata Y, Inui H, Sugiura M, and Nakano Y (2005) Triterpene glycosides of Siraitia grosvenori inhibit rat intestinal maltase and suppress the rise in blood glucose level after a single oral administration of maltose in rats. J Agric Food Chem 53:2941-2946.
35. Synenki L, Chandel NS, Budinger GR, Donnelly HK, Topin J, Eisenbart J, Jovanovic B, and Jain M (2007) Bronchoalveolar lavage fluid from patients with acute lung injury/acute respiratory distress syndrome induces myofibroblast differentiation. Crit Care Med 35:842-848.
36. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, and Crystal RG (1979) Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 120:893-899.
37. Todd NW, Luzina IG, and Atamas SP (2012) Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 5:11.
38. van der Velden JL, Ye Y, Nolin JD, Hoffman SM, Chapman DG, Lahue KG, Abdalla S, Chen P, Liu Y, Bennett B, et al. (2016) JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin Transl Med 5:36.
39. Vittal R, Fisher A, Gu H, Mickler EA, Panitch A, Lander C, Cummings OW, Sandusky GE, and Wilkes DS (2013) Peptide-mediated inhibition of mitogenactivated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 49:47-57.
40. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, and Borok Z (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-b1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321-1332.
41. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524-529.
42. Xiao G, Chen Z, Li WN, Wang Q, and Liao CX (2012) Protective effect of mogroside on carbon tetrachloride-induced hepatic fibrosis rats. Shandong Med 52:19-24.
43. Xiao G and Wang Q (2013) Experiment study on the hepatoprotective effect of mogrosides. Chin J Exp Traditional Med Formulae 19:196-200.
44. Xu F, Li DP, Huang ZC, Lu FL, Wang L, Huang YL, Wang RF, Liu GX, Shang MY, and Cai SQ (2015) Exploring in vitro, in vivo metabolism of mogroside V and distribution of its metabolites in rats by HPLC-ESI-IT-TOF-MSn. J Pharm Biomed Anal 115:418-430.
45. Yang HZ, Wang JP, Mi S, Liu HZ, Cui B, Yan HM, Yan J, Li Z, Liu H, Hua F, et al. (2012) TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol 180:275-292.
46. Yoshida K, Kuwano K, Hagimoto N, Watanabe K, Matsuba T, Fujita M, Inoshima I, and Hara N (2002) MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 198:388-396.
47. Yoshimura S, Nishimura Y, Nishiuma T, Yamashita T, Kobayashi K, and Yokoyama M (2006) Overexpression of nitric oxide synthase by the endothelium attenuates bleomycin-induced lung fibrosis and impairs MMP-9/TIMP-1 balance. Respirology 11:546-556.
48. You XY, Xue Q, Fang Y, Liu Q, Zhang CF, Zhao C, Zhang M, and Xu XH (2015) Preventive effects of Ecliptae Herba extract and its component, ecliptasaponin A, on bleomycin-induced pulmonary fibrosis in mice. J Ethnopharmacol 175:172-180.